Resveratrol given intraperitoneally does not inhibit the growth of high-risk             t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model.
The efficacy of resveratrol as a preventive agent against the growth of             t(4;11) acute lymphoblastic leukemia (ALL) was evaluated in NOD.CB17-Prkdcscid/J             mice engrafted with the human t(4;11) ALL SEM cell line. SEM cells were injected             into the tail vein and engraftment was monitored by flow cytometry. Once engraftment             was observed, mice were injected intraperitoneally with resveratrol (10 mg/kg             body weight) dissolved in dimethylsulfoxide (DMSO) or DMSO alone (control) every             other day, or vincristine (0.5 mg/kg body weight) 3 times per week for 4 weeks             (n=16 per group). Comparisons of the percent of human leukemia cells in blood             and survival curves showed resveratrol did not inhibit progression of the disease.             Liquid chromatography-tandem mass spectrometry analyses of mouse sera showed resveratrol             was rapidly metabolized to glucuronidated and sulfated forms 1 h post-injection,             with low to no resveratrol or metabolites observed in sera by 24-48 h. These data             indicate that in contrast to findings in in vitro models, parenterally administered             resveratrol does not have potential as a preventive agent against high risk t(4;11)             ALL.
United States Department of Agriculture, Agricultural Research Service, Western Human Nutrition Research Center, 430 West Health Sciences Drive, Davis, CA 95616, USA. susan.zunino@ars.usda.gov
Susan J
SJ
Zunino
David H
DH
Storms
John W
JW
Newman
Theresa L
TL
Pedersen
Carl L
CL
Keen
Jonathan M
JM
Ducore
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*
D016588:Anticarcinogenic Agents; D000972:Antineoplastic Agents, Phytogenic; D013267:Stilbenes; D000077185:Resveratrol